OLMA
Olema Pharmaceuticals, Inc.
Price Chart
Latest Quote
$10.00
+0.49 (+5.15%)
Current Price
| Previous Close | $9.51 |
| Open | $9.55 |
| Day High | $10.02 |
| Day Low | $9.46 |
| Volume | 2,547,603 |
Stock Information
| Shares Outstanding | 87.35M |
| Total Debt | $3.96M |
| Cash Equivalents | $505.35M |
| Net Income | $-185.15M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $873.47M |
| EPS (TTM) | $-2.03 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $372.08M |
| Income | $-185.15M |
| Book/sh | $5.50 |
| Cash/sh | $5.79 |
| Employees | 137 |
Financial Ratios
| Quick Ratio | 10.79 |
| Current Ratio | 10.88 |
| Debt/Eq | 0.82 |
Returns & Margins
| ROA | -25.50% |
| ROE | -42.86% |
Ownership
| Insider Ownership | 1.80% |
| Institutional Ownership | 119.42% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.03 |
| P/B | 1.82 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $40.70 |
Technical Indicators
| SMA20 | $10.94 |
| SMA50 | $13.37 |
| SMA200 | $17.07 |
| RSI | 27.07 |
| ATR | 0.7504 |
| Shares Float | 59.72M |
| Short Float | 16.59% |
| Short Ratio | 10.69 |
| Volatility | 2.00 |
| Rel Volume | 1.57 |
Performance History
| Week | +1.32% |
| Month | -28.37% |
| Quarter | -28.98% |
| 6 Months | -69.33% |
| YTD | -60.44% |
| Year | +143.90% |
| 3 Years | +11.98% |
| 5 Years | -66.57% |
| 10 Years | -79.59% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $10.00 | 2,548,100 |
| 2026-06-18 | $9.51 | 2,868,800 |
| 2026-06-17 | $9.44 | 1,733,700 |
| 2026-06-16 | $9.19 | 1,207,400 |
| 2026-06-15 | $9.88 | 1,322,000 |
| 2026-06-12 | $9.87 | 1,598,700 |
| 2026-06-11 | $9.75 | 1,985,100 |
| 2026-06-10 | $9.82 | 1,789,100 |
| 2026-06-09 | $10.45 | 1,008,900 |
| 2026-06-08 | $9.96 | 1,377,400 |
| 2026-06-05 | $10.31 | 2,519,700 |
| 2026-06-04 | $10.68 | 1,064,300 |
| 2026-06-03 | $10.51 | 1,450,400 |
| 2026-06-02 | $10.69 | 2,737,200 |
| 2026-06-01 | $12.71 | 1,346,500 |
| 2026-05-29 | $13.19 | 1,607,100 |
| 2026-05-28 | $12.76 | 1,173,500 |
| 2026-05-27 | $12.91 | 958,100 |
| 2026-05-26 | $13.55 | 1,080,200 |
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
đ° Latest News
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet
Insider Monkey âĸ 2026-06-17T15:17:05Z
Olemaâs OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap
Simply Wall St. âĸ 2026-05-25T19:05:53Z
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study
Stocktwits âĸ 2026-05-22T13:06:31Z
Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.
Barrons.com âĸ 2026-05-15T21:59:00Z
Assessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The Board
Simply Wall St. âĸ 2026-05-09T21:23:26Z
Jim Cramer on Olema Pharmaceuticals: âToo Risky for Meâ
Insider Monkey âĸ 2026-03-24T14:26:12Z
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility
Simply Wall St. âĸ 2026-03-23T15:14:43Z
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
Motley Fool âĸ 2026-03-22T16:28:37Z
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks âĸ 2026-03-18T13:35:02Z
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Motley Fool âĸ 2026-03-16T23:02:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $178,698,000 | $142,258,000 | $104,961,000 | $106,988,000 |
| Other Income Expense | $23,000 | $102,000 | $-19,000 | $-27,000 |
| Other Non Operating Income Expenses | $23,000 | $102,000 | $-19,000 | $-27,000 |
| Net Non Operating Interest Income Expense | $16,224,000 | $12,682,000 | $8,325,000 | $2,228,000 |
| Operating Expense | $178,698,000 | $142,258,000 | $104,961,000 | $106,988,000 |
| General And Administrative Expense | $21,001,000 | $17,741,000 | $18,821,000 | $24,714,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Net Interest Income | $16,224,000 | $12,682,000 | $8,325,000 | $2,228,000 |
| Interest Income | $16,224,000 | $12,682,000 | $8,325,000 | $2,228,000 |
| Normalized Income | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Net Income From Continuing And Discontinued Operation | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Total Operating Income As Reported | $-178,698,000 | $-142,258,000 | $-104,961,000 | $-106,988,000 |
| Net Income Common Stockholders | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Net Income | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Net Income Including Noncontrolling Interests | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Net Income Continuous Operations | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Pretax Income | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Interest Income Non Operating | $16,224,000 | $12,682,000 | $8,325,000 | $2,228,000 |
| Operating Income | $-178,698,000 | $-142,258,000 | $-104,961,000 | $-106,988,000 |
| Per Share | ||||
| Diluted EPS | $-1.87 | $-2.20 | $-2.14 | $-2.62 |
| Basic EPS | $-1.87 | $-2.20 | $-2.14 | $-2.62 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-178,208,000 | $-141,865,000 | $-104,584,000 | $-106,631,000 |
| Reconciled Depreciation | $490,000 | $393,000 | $377,000 | $357,000 |
| EBITDA (Bullshit earnings) | $-178,208,000 | $-141,865,000 | $-104,584,000 | $-106,631,000 |
| EBIT | $-178,698,000 | $-142,258,000 | $-104,961,000 | $-106,988,000 |
| Diluted Average Shares | $87,006,027 | $58,743,522 | $45,247,098 | $39,995,460 |
| Basic Average Shares | $87,006,027 | $58,743,522 | $45,247,098 | $39,995,460 |
| Diluted NI Availto Com Stockholders | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Research And Development | $157,697,000 | $124,517,000 | $86,140,000 | $82,274,000 |
| Selling General And Administration | $21,001,000 | $17,741,000 | $18,821,000 | $24,714,000 |
| Other Gand A | $21,001,000 | $17,741,000 | $18,821,000 | $24,714,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $478,559,000 | $408,964,000 | $253,895,000 | $197,546,000 |
| Total Assets | $533,430,000 | $450,979,000 | $276,945,000 | $215,645,000 |
| Total Non Current Assets | $17,978,000 | $12,506,000 | $10,432,000 | $6,746,000 |
| Other Non Current Assets | $892,000 | $698,000 | - | $2,771,000 |
| Non Current Prepaid Assets | $15,666,000 | $9,748,000 | $7,173,000 | $2,771,000 |
| Current Assets | $515,452,000 | $438,473,000 | $266,513,000 | $208,899,000 |
| Other Current Assets | $1,586,000 | $366,000 | $1,681,000 | $1,516,000 |
| Prepaid Assets | $4,373,000 | $1,901,000 | $2,352,000 | $2,643,000 |
| Receivables | $4,056,000 | $2,120,000 | $673,000 | $319,000 |
| Taxes Receivable | $919,000 | $0 | - | - |
| Accrued Interest Receivable | $3,137,000 | $2,120,000 | $673,000 | $319,000 |
| Cash Cash Equivalents And Short Term Investments | $505,437,000 | $434,086,000 | $261,807,000 | $204,421,000 |
| Cash And Cash Equivalents | $48,301,000 | $139,480,000 | $68,539,000 | $23,702,000 |
| Debt | ||||
| Total Debt | $4,193,000 | $1,429,000 | $2,417,000 | $2,565,000 |
| Long Term Debt And Capital Lease Obligation | $3,069,000 | $257,000 | $1,429,000 | $1,550,000 |
| Long Term Debt | $3,000,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $1,124,000 | $1,172,000 | $988,000 | $1,015,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $54,871,000 | $42,015,000 | $23,050,000 | $18,099,000 |
| Total Non Current Liabilities Net Minority Interest | $3,069,000 | $257,000 | $1,429,000 | $1,550,000 |
| Current Liabilities | $51,802,000 | $41,758,000 | $21,621,000 | $16,549,000 |
| Payables And Accrued Expenses | $42,425,000 | $34,925,000 | $15,168,000 | $10,934,000 |
| Payables | $9,253,000 | $4,460,000 | $2,771,000 | $442,000 |
| Accounts Payable | $9,253,000 | $4,460,000 | $2,698,000 | $374,000 |
| Total Tax Payable | - | $41,000 | $73,000 | $68,000 |
| Other Current Liabilities | - | - | - | $82,000 |
| Equity | ||||
| Common Stock Equity | $478,559,000 | $408,964,000 | $253,895,000 | $197,546,000 |
| Total Equity Gross Minority Interest | $478,559,000 | $408,964,000 | $253,895,000 | $197,546,000 |
| Stockholders Equity | $478,559,000 | $408,964,000 | $253,895,000 | $197,546,000 |
| Gains Losses Not Affecting Retained Earnings | $621,000 | $143,000 | $347,000 | $-1,813,000 |
| Other Equity Adjustments | $621,000 | $143,000 | $347,000 | $-1,813,000 |
| Retained Earnings | $-597,557,000 | $-435,106,000 | $-305,632,000 | $-208,977,000 |
| Other | ||||
| Ordinary Shares Number | $81,376,449 | $74,312,608 | $54,992,784 | $40,287,097 |
| Share Issued | $81,376,449 | $74,312,608 | $55,097,118 | $40,287,097 |
| Tangible Book Value | $478,559,000 | $408,964,000 | $253,895,000 | $197,546,000 |
| Invested Capital | $481,559,000 | $408,964,000 | $253,895,000 | $197,546,000 |
| Working Capital | $463,650,000 | $396,715,000 | $244,892,000 | $192,350,000 |
| Capital Lease Obligations | $1,193,000 | $1,429,000 | $2,417,000 | $2,565,000 |
| Total Capitalization | $481,559,000 | $408,964,000 | $253,895,000 | $197,546,000 |
| Additional Paid In Capital | $1,075,487,000 | $843,920,000 | $559,176,000 | $408,333,000 |
| Capital Stock | $8,000 | $7,000 | $4,000 | $3,000 |
| Common Stock | $8,000 | $7,000 | $4,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $69,000 | $257,000 | $1,429,000 | $1,550,000 |
| Current Capital Lease Obligation | $1,124,000 | $1,172,000 | $988,000 | $1,015,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,253,000 | $5,661,000 | $5,465,000 | $4,518,000 |
| Current Accrued Expenses | $33,172,000 | $30,465,000 | $12,397,000 | $10,492,000 |
| Net PPE | $1,420,000 | $2,060,000 | $3,259,000 | $3,975,000 |
| Gross PPE | $1,420,000 | $2,060,000 | $3,259,000 | $3,975,000 |
| Other Properties | $1,420,000 | $2,060,000 | $3,259,000 | $3,975,000 |
| Other Short Term Investments | $457,136,000 | $294,606,000 | $193,268,000 | $180,719,000 |
| Treasury Shares Number | - | - | $104,334 | - |
| Accumulated Depreciation | - | - | - | $-581,000 |
| Machinery Furniture Equipment | - | - | - | $59,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-146,716,000 | $-104,510,000 | $-83,727,000 | $-82,428,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-146,716,000 | $-104,351,000 | $-83,727,000 | $-82,065,000 |
| Cash Flow From Continuing Operating Activities | $-146,716,000 | $-104,351,000 | $-83,727,000 | $-82,065,000 |
| Operating Gains Losses | - | $9,000 | $111,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $-155,760,000 | $-93,526,000 | $-4,851,000 | $91,479,000 |
| Cash Flow From Continuing Investing Activities | $-155,760,000 | $-93,526,000 | $-4,851,000 | $91,479,000 |
| Capital Expenditure | - | $-159,000 | - | $-363,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $205,390,000 | $266,288,000 | $129,736,000 | $0 |
| Financing Cash Flow | $211,297,000 | $268,818,000 | $133,415,000 | $476,000 |
| Cash Flow From Continuing Financing Activities | $211,297,000 | $268,818,000 | $133,415,000 | $476,000 |
| Net Other Financing Charges | $-6,514,000 | - | - | - |
| Net Common Stock Issuance | $205,390,000 | $266,288,000 | $129,736,000 | $0 |
| Common Stock Issuance | $205,390,000 | $266,288,000 | $129,736,000 | $0 |
| Repurchase Of Capital Stock | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $3,000,000 | $0 | - | - |
| End Cash Position | $48,301,000 | $139,480,000 | $68,539,000 | $23,702,000 |
| Beginning Cash Position | $139,480,000 | $68,539,000 | $23,702,000 | $13,812,000 |
| Changes In Cash | $-91,179,000 | $70,941,000 | $44,837,000 | $9,890,000 |
| Proceeds From Stock Option Exercised | $9,421,000 | $2,530,000 | $3,679,000 | $476,000 |
| Net Issuance Payments Of Debt | $3,000,000 | $0 | - | - |
| Net Long Term Debt Issuance | $3,000,000 | $0 | - | - |
| Long Term Debt Issuance | $3,000,000 | $0 | - | - |
| Net Investment Purchase And Sale | $-155,760,000 | $-93,367,000 | $-4,865,000 | $91,842,000 |
| Sale Of Investment | $344,962,000 | $301,592,000 | $250,760,000 | $305,502,000 |
| Purchase Of Investment | $-500,722,000 | $-394,959,000 | $-255,625,000 | $-213,660,000 |
| Net PPE Purchase And Sale | $0 | $-159,000 | $14,000 | $-363,000 |
| Purchase Of PPE | $0 | $-159,000 | $0 | $-363,000 |
| Change In Working Capital | $2,775,000 | $9,164,000 | $-589,000 | $3,022,000 |
| Change In Other Current Liabilities | $9,740,000 | $10,040,000 | $1,717,000 | $5,744,000 |
| Change In Other Current Assets | $-6,145,000 | $-2,957,000 | $-5,324,000 | $-1,114,000 |
| Change In Payables And Accrued Expense | $4,598,000 | $2,510,000 | $2,324,000 | $351,000 |
| Change In Payable | $4,598,000 | $2,510,000 | $2,324,000 | $351,000 |
| Change In Account Payable | $4,598,000 | $2,510,000 | $2,324,000 | $351,000 |
| Change In Prepaid Assets | $-5,418,000 | $-429,000 | $694,000 | $-1,959,000 |
| Other Non Cash Items | $-5,116,000 | $-7,025,000 | $-4,227,000 | $514,000 |
| Stock Based Compensation | $17,586,000 | $22,582,000 | $17,256,000 | $18,829,000 |
| Depreciation Amortization Depletion | $490,000 | $393,000 | $377,000 | $357,000 |
| Depreciation And Amortization | $490,000 | $393,000 | $377,000 | $357,000 |
| Gain Loss On Sale Of PPE | $0 | $9,000 | $111,000 | $0 |
| Net Income From Continuing Operations | $-162,451,000 | $-129,474,000 | $-96,655,000 | $-104,787,000 |
| Sale Of PPE | - | $0 | $14,000 | $0 |
| Amortization Of Securities | - | - | - | $-787,000 |
| Preferred Stock Payments | - | - | - | - |
Fetched: 2026-06-22